Emodin suppresses proliferation, migration and invasion in ovarian cancer cells by down regulating ILK in vitro and in vivo
Open Access
- 1 July 2017
- journal article
- retracted article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 10, 3579-3589
Abstract
Objective: Although our previous studies have confirmed that 1, 3, 8-trihydroxy-6-methylanthraquinone (emodin) inhibits migration and invasion in epithelial ovarian cancer (EOC) cells, the underlying molecular mechanism remains unknown. Here, the aim was to investigate the effects of emodin on EOC cells and to study further the mechanism underlying this process, both in vitro and in vivo. Materials and methods: Cell proliferation was evaluated by the methylthiazolyl tetrazolium assay. Cell migration and invasion abilities were tested using the transwell assay. The expression of integrin-linked kinase (ILK) and epithelial–mesenchymal transition (EMT)-associated factors were measured with western blotting. Results: Exogenous ILK enhanced the proliferation, migration and invasion properties of A2780 and SK-OV-3 cells. After treatment with emodin, the survival rate of cells was gradually reduced, including those of SK-OV-3/pLVX-ILK and A2780/pLVX-ILK cells, with increasing emodin concentrations. The migration and invasion abilities of A2780 and SK-OV-3 cells were effectively increased by the transfection of pLVX-ILK, which could be abrogated by following this with 48 hours of emodin treatment. Treatment with emodin significantly downregulated the expression of ILK and EMT-related proteins. So, emodin suppressed proliferation, migration and invasion in ovarian cancer cells by downregulating ILK in vitro. SK-OV-3/pLVX-Con and SK-OV-3/pLVX-ILK cells were used to generate xenografts in nude mice. Tumors grew more rapidly in the SK-OV-3/pLVX-ILK group compared with the control group, and this could be significantly inhibited by emodin. Also, the expression of E-cadherin was downregulated, while the expression of Slug, MMP-9 and Vimentin were upregulated in the SK-OV-3/pLVX-ILK group, and this could be reversed by following treatment with emodin. Emodin did not demonstrate target toxicity on hepatocytes, nephrocytes and cardiomyocytes. Conclusion: Emodin suppresses proliferation, migration and invasion in ovarian cancer by targeting ILK.Keywords
This publication has 38 references indexed in Scilit:
- Silencing of integrin-linked kinase suppresses in vivo tumorigenesis of human ovarian carcinoma cellsMolecular Medicine Reports, 2013
- Protein kinase CK2α is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT-related genesJournal of Translational Medicine, 2011
- The importance of integrin‐linked kinase in the regulation of bladder cancer invasionInternational Journal of Cancer, 2011
- EMT, the cytoskeleton, and cancer cell invasionCancer and Metastasis Reviews, 2009
- The epithelial–mesenchymal transition: new insights in signaling, development, and diseaseJournal of Cell Biology, 2006
- Cell-Free 59 kDa Immunoreactive Integrin-Linked KinaseClinical Cancer Research, 2004
- Integrin‐linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluidThe Journal of Pathology, 2003
- αv integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cellsOncogene, 2003
- DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathwayOncogene, 2001
- Cell–substrate interactions and signaling through ILKCurrent Opinion in Cell Biology, 2000